SurgihoneyRO™ is the first published, antimicrobial wound dressing that has been tested against the 12 priority MDR bacterial strains, and has been shown to be effective against almost all these organisms1
The term reactive oxygen species (ROS) describes highly reactive molecules containing reduced oxygen or oxygen atoms with extra electrons. Members of the ROS family include superoxide anion O2–, peroxide O2–2, hydrogen peroxide H2O2.
ROS are naturally occurring in the body. Basal ROS levels maintain normal cell functioning and homeostasis2, while increased amounts induce a cell-mediated antimicrobial defence response3.
ROS are part of the innate immune response, and play a critical role in wound healing and infection control at the wound site4. They are released within minutes of epithelial injury, signalling rapid recruitment of leukocytes5. ROS directly damage microbes that invade tissues6. In wound healing, ROS are secondary messengers to many immunocytes and non-lymphoid cells, and regulate angiogenesis, haemostasis and tissue repair7.
Reactive Oxygen® is the antimicrobial mechanism for SurgihoneyRO™. In contact with moisture, SurgihoneyRO™ releases Reactive Oxygen®.
In vitro studies have shown that Reactive Oxygen® at close to naturally occurring levels:
- Stimulates proliferation of human fibroblasts and vascular endothelial cells5,13
- Stimulates angiogenesis via vascular endothelial growth factor (VEGF) signalling14
- Promotes keratinocyte cell migration and proliferation15
A controlled and sustained level of H2O2 that is non-harmful and non-toxic to surrounding tissue, is a therapeutic opportunity for wound care. SurgihoneyRO™ does this through the release of Reactive Oxygen®. To find out more on the technology of SurgihoneyRO™ and Reactive Oxygen®, read the Reactive Oxygen Made Easy.
Scientists from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, the research arm of the NHS, demonstrated SurgihoneyRO™ is highly effective at tackling a wide variety of bacterial biofilm found in chronic wounds in vitro.
“Given the threat posed by antimicrobial resistance and the ever-increasing need to find new solutions to treat infections, SurgihoneyRO™ has real potential as a new wound care agent to kill bacteria and disrupt biofilm.” – Fenella Halstead, Clinical scientist, National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre.
SurgihoneyRO™ has been successfully used for infection prevention, eradication of MDR bacterial strains and prevention of surgical site infections and intravascular line care in vivo15,16,17.
The Reactive Oxygen® released by SurgihoneyRO™ is a broad-spectrum antimicrobial against wound-relevant MDR bacterial strains and has been shown to prevent and disrupt and eradicate mature biofilm.
SurgihoneyRO™ presents one option against the growing global issue of antimicrobial resistance.